Join our daily newsletter At The Bell to receive exclusive market insights
- Archer Materials (AXE) has seen its biochip technology filed in the US and assigned a US application number
- Archer says it considers this a key strategic move to protect and commercialise its intellectual property
- Meanwhile, patent applications for Archer’s 12CQ chip are progressing in later stages of the patent granting procedures in the US and Europe
- Archer Materials are up 19.4 per cent to trade at $2.83 at 12:52 pm AEST
Archer Materials (AXE) has seen its biochip technology filed for a patent in the US and assigned a US application number.
Archer is a technology company developing and commercialising advanced semiconductor devices, including chips relevant to quantum computing and medical diagnostics.
The company’s 100 per cent owned patent application, related to its graphene-based biochip technology, has progressed to the national phase of the patent granting procedure. The company says this allows the company to pursue and achieve patent granting in the US for the respective patent application.
Archer says it considers this move key to protecting and commercialising its IP in an important jurisdiction.
A national phase entry has also been sought by the company in Australia. As patents are only granted in each country by the relevant national patent office, the national phase entry is a key requirement in the process for the granting of a patent internationally.
This follows the news that Archer expanded its access to institutional deep tech infrastructure and hired new personnel to develop its biochip technology.
Meanwhile, patent applications for Archer’s 12CQ chip are progressing in later stages of the patent granting procedures in the US and Europe.
Archer Materials were up 19.4 per cent to trade at $2.83 at 12:52 pm AEST.
